{"product_id":"retatrutide-60mg-uae","title":"Retatrutide 60mg UAE: 3D Pen, Research Profile \u0026 Product Guide","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg UAE\u003c\/span\u003e\u003cspan\u003e is a highly specific search topic for researchers and readers looking for information about Retatrutide, its investigational triple-agonist mechanism, clinical development, and 60mg product formats. The product shown here is labeled RETATRUTIDE 3D 60mg\/3ml and is presented in a pre-filled pen format.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide, also known by the development code LY3437943, is being investigated as a single molecule capable of activating three metabolic hormone receptors: GIP, GLP-1 and glucagon receptors. Lilly describes Retatrutide as an investigational triple hormone receptor agonist and continues to evaluate it through its clinical development program.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe 60mg\/3ml presentation shown in the product image should not be confused with an approved Retatrutide medicine. Packaging claims describe the pictured item; they do not establish regulatory approval, authenticity, clinical equivalence, purity, or authorization.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg UAE Product Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"169\"\u003e\n\u003ccol width=\"282\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eProduct Detail\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInformation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eProduct name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 3D\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDevelopment code\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLY3437943\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLabeled strength\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e60mg\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLabeled volume\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e3ml\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat shown\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePre-filled pen\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePackage statement\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e1 pen contains 5 doses\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePackage marking\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor export only\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMechanism under study\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGIP \/ GLP-1 \/ glucagon receptor agonism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDevelopment status\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInvestigational\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eUAE status\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eUnauthorized for routine public use\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe specifications above referring to 60mg\/3ml, five doses and export-only status are taken from the packaging visible in the supplied product image and should therefore be understood as label information rather than independent laboratory verification.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is Retatrutide?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide is an investigational molecule being developed by Eli Lilly. Unlike single-receptor approaches, Retatrutide is designed to activate three different receptors within one molecule:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGIP receptor\u003c\/span\u003e\u003cspan\u003e — involved in metabolic and insulin-related signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 receptor\u003c\/span\u003e\u003cspan\u003e — associated with glucose regulation, appetite signaling and metabolic processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGlucagon receptor\u003c\/span\u003e\u003cspan\u003e — involved in energy and metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis three-receptor activity is why Retatrutide is commonly described as a triple agonist. Lilly specifically notes that the informal term “GLP-3” is scientifically inaccurate; triple hormone receptor agonist is the more appropriate description.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg UAE and Current Clinical Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInterest around \u003c\/span\u003e\u003cspan\u003eRetatrutide 60mg UAE\u003c\/span\u003e\u003cspan\u003e should be separated from the doses and formulations evaluated in controlled clinical trials. A commercial-looking product labeled 60mg does not mean that 60mg represents an approved clinical dose or approved presentation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide has progressed through a substantial Phase 3 research program. ClinicalTrials.gov lists studies evaluating LY3437943 in obesity, overweight, type 2 diabetes and cardiovascular-related populations. For example, TRIUMPH-3 evaluates efficacy and safety in participants with severe obesity and established cardiovascular disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn May 2026, Lilly reported topline TRIUMPH-1 results in which participants assigned to the 12mg group had an average body-weight reduction of 28.3% at 80 weeks. These results come from a controlled clinical development program and should not be extrapolated to third-party products labeled “Retatrutide 60mg.”\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdditional Phase 3 topline results were announced in July 2026 for TRIUMPH-2 and TRIUMPH-3. Lilly reported average weight reductions of up to 20.8% and 22.6%, respectively, at 80 weeks in the studied populations. The company said it plans a U.S. regulatory submission in Q1 2027.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 3D 60mg\/3ml Pen Format\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe pictured Retatrutide 3D product uses a pen-style presentation rather than a conventional standalone vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eVisible packaging states:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eRETATRUTIDE 3D\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003e60mg\/3ml\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003e1 pen contains 5 doses\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eFor export only\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe pen itself is also labeled as a Retatrutide 60mg\/3ml product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThese characteristics can be useful for product identification and catalog organization. They should not, however, be interpreted as evidence that the product has been authorized by health regulators.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor SEO purposes, this distinction is especially important when discussing Retatrutide 60mg UAE, because readers may otherwise assume that a product appearing online has the same regulatory status as a licensed medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide Research in the UAE\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eUAE regulatory context is particularly important.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eOn 6 March 2026, Abu Dhabi's Department of Health issued Circular No. 40\/2026 warning healthcare facilities, professionals and the public against unauthorized Retatrutide products. The circular states that Retatrutide remains under clinical development and is not authorized or licensed for use or distribution. It also warns about products of unknown origin being promoted online.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLilly similarly states that Retatrutide has not yet been approved by any regulatory agency and is not currently available for public use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTherefore, references to Retatrutide 60mg UAE on this page describe the research compound and pictured product format; they should not be interpreted as indicating UAE regulatory approval.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhy Product Verification Matters\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor any product represented as an investigational research compound, the packaging alone cannot establish identity or quality.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRelevant verification may include documentation concerning:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIdentity:\u003c\/span\u003e\u003cspan\u003e whether analytical testing corresponds to the compound stated on the label.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity:\u003c\/span\u003e\u003cspan\u003e whether appropriate analytical methods have been used to characterize the sample.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBatch traceability:\u003c\/span\u003e\u003cspan\u003e whether lot or batch information can be connected to supporting documentation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStorage information:\u003c\/span\u003e\u003cspan\u003e whether documented handling conditions are available.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePackaging consistency:\u003c\/span\u003e\u003cspan\u003e whether the outer box, pen labeling and associated documentation correspond with one another.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThese considerations become especially important with investigational compounds because they do not have the same authorized commercial supply chain as approved medicines.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eFrequently Asked Questions\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat is Retatrutide 60mg UAE?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe phrase Retatrutide 60mg UAE refers here to UAE-focused information about a product presented as Retatrutide 3D with a labeled strength of 60mg\/3ml. Retatrutide itself remains an investigational compound.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eIs Retatrutide a GLP-1 compound?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide has GLP-1 receptor activity, but describing it only as a GLP-1 agonist is incomplete. It is designed to activate GIP, GLP-1 and glucagon receptors.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat does the Retatrutide 3D package contain?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe supplied product image states 60mg\/3ml and “1 pen contains 5 doses.” These are packaging statements and are not independent verification of the contents.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eIs Retatrutide approved in the UAE?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCurrent official information does not support presenting Retatrutide as an approved UAE medicine. Abu Dhabi DoH specifically issued a warning against unauthorized Retatrutide products in March 2026.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eIs Retatrutide still in clinical development?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eYes. Lilly describes Retatrutide as investigational, with an ongoing clinical development program, and says it has not yet received regulatory approval.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eConclusion\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg UAE\u003c\/span\u003e\u003cspan\u003e is a useful product-specific topic for understanding the pictured Retatrutide 3D 60mg\/3ml pen alongside the broader scientific development of LY3437943. Retatrutide is being investigated as a GIP, GLP-1 and glucagon triple receptor agonist and has progressed through multiple Phase 3 studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eHowever, clinical research findings should not be treated as verification of third-party Retatrutide products. The pictured 60mg\/3ml pen remains a separately labeled product presentation, while Retatrutide itself remains investigational and unauthorized for routine public use in the UAE.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eDisclaimer\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis content is provided for research, product-identification and educational purposes only. It is not medical advice, a dosing or administration guide, or evidence of regulatory approval. Product-label information should not be interpreted as independent confirmation of composition, purity, safety or authenticity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44580175872051,"sku":null,"price":1600.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0702\/4676\/0499\/files\/Retatrutide_60mg_UAE_3D_60mg_3ml_pre-filled_pen.jpg?v=1788259977","url":"https:\/\/purenessx.store\/products\/retatrutide-60mg-uae","provider":"Pureness X","version":"1.0","type":"link"}